United States Biotechnology & Medical Research

Werewolf Therapeutics Inc (HOWL)

Track

Track

Werewolf Therapeutics Inc. experienced multiple planned and proposed sales by shareholders and insiders throughout June and July 2026. Luke Evnin and various MPM-affiliated entities executed these divestments. The most recent activity occurred on July 7, 2026, marking the conclusion of this period of selling interest.
Ticker: HOWL Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Werewolf Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
67.35
Quantity 47,445 -45.0%
Value US$4,337,834
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
184.28
Quantity 26,017 -43.5%
Value US$2,059,515
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.30
Quantity 157,084 -52.3%
Value US$47,125
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.37
Quantity 76,928 -20.4%
Value US$28,463
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.40
Quantity 60,547 -13.8%
Value US$24,219
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.40
Quantity 24,946 -5.4%
Value US$9,978
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.44
Quantity 20,072 -4.2%
Value US$8,832
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.42
Quantity 29,749 -5.8%
Value US$12,495
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.45
Quantity 29,595 -5.5%
Value US$13,318
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.47
Quantity 80,459 -12.9%
Value US$37,816
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.45
Quantity 32,556 -5.0%
Value US$14,650
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.46
Quantity 27,698 -4.1%
Value US$12,741
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.48
Quantity 80,852 -10.6%
Value US$38,809
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.47
Quantity 67,950 -8.2%
Value US$31,936
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.45
Quantity 87,425 -9.5%
Value US$39,341
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.42
Quantity 36,387 -3.8%
Value US$15,283
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.43
Quantity 85,895 -8.2%
Value US$36,935
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.45
Quantity 62,970 -5.7%
Value US$28,336
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.50
Quantity 22,184 -2.0%
Value US$11,092
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.54
Quantity 44,679 -3.8%
Value US$24,127
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.64
Quantity 67,885 -5.5%
Value US$43,446
1.8
EVNIN LUKE Non-Executive Director
Transaction date
Planned sale
Price
0.67
Quantity 33,948 -2.7%
Value US$22,745
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-08 2026-07-07 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
47,445 -45.0%
67.35
US$4,337,834 		47,445 -45.0% 67.35 US$4,337,834
2026-07-08 2026-07-06 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
26,017 -43.5%
184.28
US$2,059,515 		26,017 -43.5% 184.28 US$2,059,515
2026-07-06 2026-07-06 PrS Proposed sale
2.3
UBS Oncology Impact Fund, L.P.

Shareholder
86,909
136.30
US$1,628,163 		86,909 136.30 US$1,628,163
2026-07-06 2026-07-06 PrS Proposed sale
MPM Asset Management LLC

Shareholder
15,341
0.34
US$5,222 		15,341 0.34 US$5,222
2026-07-06 2026-07-06 PrS Proposed sale
MPM Asset Management Investors BV2014 LLC

Shareholder
3,332
0.34
US$1,134 		3,332 0.34 US$1,134
2026-07-06 2026-07-06 PrS Proposed sale
MPM BioVentures 2014 (B), L.P.

Shareholder
6,459
0.34
US$2,199 		6,459 0.34 US$2,199
2026-07-06 2026-07-06 PrS Proposed sale
MPM Oncology Innovations Fund, L.P.

Shareholder
21,194
0.34
US$7,214 		21,194 0.34 US$7,214
2026-07-06 2026-07-06 PrS Proposed sale
3.3
MPM BioVentures 2014, L.P.

Shareholder
96,873
0.34
US$32,976 		96,873 0.34 US$32,976
2026-06-29 2026-06-29 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
157,084 -52.3%
0.30
US$47,125 		157,084 -52.3% 0.30 US$47,125
2026-06-29 2026-06-29 PrS Proposed sale
MPM Asset Management Investors BV2014 LLC

Shareholder
3,657
0.32
US$1,181 		3,657 0.32 US$1,181
2026-06-29 2026-06-29 PrS Proposed sale
MPM Asset Management LLC

Shareholder
16,830
0.32
US$5,436 		16,830 0.32 US$5,436
2026-06-29 2026-06-29 PrS Proposed sale
MPM Oncology Innovations Fund, L.P.

Shareholder
23,248
0.32
US$7,509 		23,248 0.32 US$7,509
2026-06-29 2026-06-29 PrS Proposed sale
3.3
MPM BioVentures 2014, L.P.

Shareholder
106,262
0.32
US$34,323 		106,262 0.32 US$34,323
2026-06-29 2026-06-29 PrS Proposed sale
MPM BioVentures 2014 (B), L.P.

Shareholder
7,087
0.32
US$2,289 		7,087 0.32 US$2,289
2026-06-29 2026-06-29 PrS Proposed sale
2.3
UBS Oncology Impact Fund, L.P.

Shareholder
87,916
0.32
US$28,397 		87,916 0.32 US$28,397
2026-06-22 2026-06-17 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
27,695 -8.4%
0.35
US$9,693 		27,695 -8.4% 0.35 US$9,693
2026-06-22 2026-06-17 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
27,695 -8.4%
0.35
US$9,693 		27,695 -8.4% 0.35 US$9,693
2026-06-22 2026-06-17 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
389,216 -8.4%
0.35
US$136,226 		389,216 -8.4% 0.35 US$136,226
2026-06-22 2026-06-17 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
389,216 -8.4%
0.35
US$136,226 		389,216 -8.4% 0.35 US$136,226
2026-06-16 2026-06-16 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
9,939 -2.9%
0.37
US$3,677 		9,939 -2.9% 0.37 US$3,677
2026-06-16 2026-06-16 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
139,686 -2.9%
0.37
US$51,684 		139,686 -2.9% 0.37 US$51,684
2026-06-16 2026-06-15 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
8,554 -2.4%
0.39
US$3,336 		8,554 -2.4% 0.39 US$3,336
2026-06-16 2026-06-15 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
120,216 -2.4%
0.39
US$46,884 		120,216 -2.4% 0.39 US$46,884
2026-06-16 2026-06-12 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
11,322 -3.1%
0.40
US$4,529 		11,322 -3.1% 0.40 US$4,529
2026-06-16 2026-06-12 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
159,119 -3.1%
0.40
US$63,648 		159,119 -3.1% 0.40 US$63,648
2026-06-11 2026-06-11 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
17,437 -4.6%
0.38
US$6,626 		17,437 -4.6% 0.38 US$6,626
2026-06-11 2026-06-11 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
17,437 -4.6%
0.38
US$6,626 		17,437 -4.6% 0.38 US$6,626
2026-06-11 2026-06-11 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
245,066 -4.6%
0.38
US$93,125 		245,066 -4.6% 0.38 US$93,125
2026-06-11 2026-06-11 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
245,066 -4.6%
0.38
US$93,125 		245,066 -4.6% 0.38 US$93,125
2026-06-11 2026-06-11 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
17,437 -4.6%
0.38
US$6,626 		17,437 -4.6% 0.38 US$6,626
2026-06-11 2026-06-11 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
245,066 -4.6%
0.38
US$93,125 		245,066 -4.6% 0.38 US$93,125
2026-06-11 2026-06-10 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
3,051 -0.8%
0.37
US$1,129 		3,051 -0.8% 0.37 US$1,129
2026-06-11 2026-06-10 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
3,051 -0.8%
0.37
US$1,129 		3,051 -0.8% 0.37 US$1,129
2026-06-11 2026-06-10 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
42,872 -0.8%
0.37
US$15,863 		42,872 -0.8% 0.37 US$15,863
2026-06-11 2026-06-10 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
42,872 -0.8%
0.37
US$15,863 		42,872 -0.8% 0.37 US$15,863
2026-06-11 2026-06-10 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
3,051 -0.8%
0.37
US$1,129 		3,051 -0.8% 0.37 US$1,129
2026-06-11 2026-06-10 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
42,872 -0.8%
0.37
US$15,863 		42,872 -0.8% 0.37 US$15,863
2026-06-11 2026-06-09 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
24,565 -6.0%
0.37
US$9,089 		24,565 -6.0% 0.37 US$9,089
2026-06-11 2026-06-09 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
24,565 -6.0%
0.37
US$9,089 		24,565 -6.0% 0.37 US$9,089
2026-06-11 2026-06-09 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
24,565 -6.0%
0.37
US$9,089 		24,565 -6.0% 0.37 US$9,089
2026-06-11 2026-06-09 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
345,235 -6.0%
0.37
US$127,737 		345,235 -6.0% 0.37 US$127,737
2026-06-10 2026-06-09 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
76,928 -20.4%
0.37
US$28,463 		76,928 -20.4% 0.37 US$28,463
2026-06-08 2026-06-08 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
60,547 -13.8%
0.40
US$24,219 		60,547 -13.8% 0.40 US$24,219
2026-06-08 2026-06-05 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
24,946 -5.4%
0.40
US$9,978 		24,946 -5.4% 0.40 US$9,978
2026-06-08 2026-06-04 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
20,072 -4.2%
0.44
US$8,832 		20,072 -4.2% 0.44 US$8,832
2026-06-03 2026-06-03 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
29,749 -5.8%
0.42
US$12,495 		29,749 -5.8% 0.42 US$12,495
2026-06-03 2026-06-02 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
29,595 -5.5%
0.45
US$13,318 		29,595 -5.5% 0.45 US$13,318
2026-06-03 2026-06-01 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
80,459 -12.9%
0.47
US$37,816 		80,459 -12.9% 0.47 US$37,816
2026-05-29 2026-05-29 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
32,556 -5.0%
0.45
US$14,650 		32,556 -5.0% 0.45 US$14,650
2026-05-29 2026-05-28 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
27,698 -4.1%
0.46
US$12,741 		27,698 -4.1% 0.46 US$12,741
2026-05-28 2026-05-28 PrS Proposed sale
3.3
MPM BioVentures 2014, L.P.

Shareholder
244,185
0.49
US$119,651 		244,185 0.49 US$119,651
2026-05-28 2026-05-28 PrS Proposed sale
MPM BioVentures 2014 (B), L.P.

Shareholder
16,287
0.49
US$7,981 		16,287 0.49 US$7,981
2026-05-28 2026-05-28 PrS Proposed sale
MPM Asset Management Investors BV2014 LLC

Shareholder
8,405
0.49
US$4,118 		8,405 0.49 US$4,118
2026-05-28 2026-05-28 PrS Proposed sale
MPM Asset Management LLC

Shareholder
38,675
0.49
US$18,951 		38,675 0.49 US$18,951
2026-05-28 2026-05-28 PrS Proposed sale
2.3
UBS Oncology Impact Fund, L.P.

Shareholder
202,029
0.49
US$98,994 		202,029 0.49 US$98,994
2026-05-28 2026-05-28 PrS Proposed sale
MPM Oncology Innovations Fund, L.P.

Shareholder
53,425
0.49
US$26,178 		53,425 0.49 US$26,178
2026-05-29 2026-05-27 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
80,852 -10.6%
0.48
US$38,809 		80,852 -10.6% 0.48 US$38,809
2026-05-26 2026-05-26 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
67,950 -8.2%
0.47
US$31,936 		67,950 -8.2% 0.47 US$31,936
2026-05-26 2026-05-22 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
87,425 -9.5%
0.45
US$39,341 		87,425 -9.5% 0.45 US$39,341
2026-05-26 2026-05-21 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
36,387 -3.8%
0.42
US$15,283 		36,387 -3.8% 0.42 US$15,283
2026-05-20 2026-05-20 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
85,895 -8.2%
0.43
US$36,935 		85,895 -8.2% 0.43 US$36,935
2026-05-20 2026-05-19 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
62,970 -5.7%
0.45
US$28,336 		62,970 -5.7% 0.45 US$28,336
2026-05-20 2026-05-18 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
22,184 -2.0%
0.50
US$11,092 		22,184 -2.0% 0.50 US$11,092
2026-05-18 2026-05-18 PrS Proposed sale
2.3
UBS Oncology Impact Fund, L.P.

Shareholder
240,280
0.52
US$123,768 		240,280 0.52 US$123,768
2026-05-18 2026-05-18 PrS Proposed sale
MPM Oncology Innovations Fund, L.P.

Shareholder
63,540
0.52
US$32,729 		63,540 0.52 US$32,729
2026-05-18 2026-05-18 PrS Proposed sale
MPM BioVentures 2014 (B), L.P.

Shareholder
19,370
0.52
US$9,977 		19,370 0.52 US$9,977
2026-05-18 2026-05-18 PrS Proposed sale
MPM Asset Management Investors BV2014 LLC

Shareholder
9,996
0.52
US$5,149 		9,996 0.52 US$5,149
2026-05-18 2026-05-18 PrS Proposed sale
3.3
MPM BioVentures 2014, L.P.

Shareholder
290,419
0.52
US$149,595 		290,419 0.52 US$149,595
2026-05-18 2026-05-18 PrS Proposed sale
MPM Asset Management LLC

Shareholder
45,998
0.52
US$23,694 		45,998 0.52 US$23,694
2026-05-13 2026-05-13 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
44,679 -3.8%
0.54
US$24,127 		44,679 -3.8% 0.54 US$24,127
2026-05-12 2026-05-12 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
67,885 -5.5%
0.64
US$43,446 		67,885 -5.5% 0.64 US$43,446
2026-05-12 2026-05-12 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
6,719 -1.6%
0.64
US$4,300 		6,719 -1.6% 0.64 US$4,300
2026-05-12 2026-05-12 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
94,432 -1.6%
0.64
US$60,436 		94,432 -1.6% 0.64 US$60,436
2026-05-12 2026-05-11 PlS Planned sale
1.8
EVNIN LUKE
Non-Executive Director
33,948 -2.7%
0.67
US$22,745 		33,948 -2.7% 0.67 US$22,745
2026-05-12 2026-05-11 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
5,812 -1.4%
0.67
US$3,894 		5,812 -1.4% 0.67 US$3,894
Explore more

More insider trading research around Werewolf Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America